Home Jurisdiction BBS releases EU growth prospectus as part of its EUR

BBS releases EU growth prospectus as part of its EUR

0

Company announcement, inside information May 9, 2022 9:05 p.m. (CEST)

NOT FOR BROADCAST, PUBLISH OR DISTRIBUTE IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS ILLEGAL.

With reference to the company’s announcement of May 6, 2022, the board of directors of BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) decided on May 6, 2022 to organize a capital increase for a total amount of approximately 4.5 million euros (the “Offer”) with two series of additional BSAs (the “BSAs”) on the basis of the authorization given by the Extraordinary General Meeting of March 17, 2022. The Offer consists of a maximum of approximately 3,490,762 new shares (the “Offered Shares”). In addition, a maximum of 872,690 new shares can be subscribed on the basis of the Warrants.

BBS has prepared an EU growth prospectus relating to the Offer approved by the Finnish Financial Supervisory Authority on May 9, 2022. The official Finnish version of the EU growth prospectus as well as its unofficial translation into English, including a summary in Swedish, are available on BBS website https://www.bbs-artebone.fi/investors/share-issue-2022/

PLC OF BBS-BIOACTIVE BONE SUBSTITUTES

For more information:

Ilkka Kangasniemi, CEO,
Phone. +35840 7080307, ​​email: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, Chief Financial Officer,
Phone. +35840 0611038, email: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lower back problems. Our goal is to provide a new generation of medical products for the treatment of bone lesions in orthopedic surgery. In the pharmaceutical sector, development and research require perseverance and courage to develop new things. We have proven it for over 20 years. Our activities are characterized by cutting-edge expertise, innovation and employees who are enthusiastic and committed to their work. ARTEBONE ® is in the final stages of product development, and we are seeking CE marking that allows for commercialization in the EU. We are a company in Oulu with a pharmaceutical factory license in Reisjärvi.

The shares of BBS-Bioactive Bone Substitutes Oyj:n have been listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi

IMPORTANT NOTICE

This press release or the information contained herein may not be distributed, directly or indirectly, in Australia, Canada, Hong Kong, Japan, Singapore, New Zealand, Singapore, South Africa or the States -United. The information contained in this press release does not constitute an offer or an invitation to buy securities in any field in which the offer, purchase or sale of such securities would be illegal prior to registration or the exemption from registration or any other approval required by title. regulations in this area. This press release does not constitute an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended, and the rules and regulations issued thereunder. BBS has not registered, and does not intend to register, any offering of securities in the United States. No steps have been taken to register the shares or the offering outside of Finland and Sweden.

The information contained herein does not constitute an offer or invitation to purchase securities in any jurisdiction. This press release is not a prospectus and does not constitute an offer, invitation or investment advice to subscribe to or purchase securities. Investors should not subscribe for or purchase securities or make any investment decisions referred to herein except on the basis of information contained in a prospectus issued by BBS.